Holly E Humphries
Overview
Explore the profile of Holly E Humphries including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voysey M, Flaxman A, Aboagye J, Aley P, Belij-Rammerstorfer S, Bibi S, et al.
Clin Exp Immunol
. 2023 Feb;
211(3):280-287.
PMID: 36729167
The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following...
2.
White A, Sibley L, Sarfas C, Morrison A, Bewley K, Churchward C, et al.
Front Immunol
. 2022 Feb;
12:801799.
PMID: 35222355
The tuberculosis vaccine, Bacille Calmette-Guerin (BCG), also affords protection against non-tuberculous diseases attributable to heterologous immune mechanisms such as trained innate immunity, activation of non-conventional T-cells, and cross-reactive adaptive immunity....
3.
Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S, et al.
Nat Med
. 2021 Sep;
27(11):2032-2040.
PMID: 34588689
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized...
4.
Bewley K, Gooch K, Thomas K, Longet S, Wiblin N, Hunter L, et al.
Sci Adv
. 2021 Sep;
7(37):eabg7996.
PMID: 34516768
There is an urgent requirement for safe and effective vaccines to prevent COVID-19. A concern for the development of new viral vaccines is the potential to induce vaccine-enhanced disease (VED)....
5.
Lambe T, Spencer A, Thomas K, Gooch K, Thomas S, White A, et al.
Commun Biol
. 2021 Jul;
4(1):915.
PMID: 34312487
Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against...
6.
Gooch K, Smith T, Salguero F, Fotheringham S, Watson R, Dennis M, et al.
Vaccine
. 2021 Jul;
39(34):4885-4894.
PMID: 34253420
Safe and effective vaccines will provide essential medical countermeasures to tackle the COVID-19 pandemic. Here, we assessed the safety, immunogenicity and efficacy of the intradermal delivery of INO-4800, a synthetic...
7.
Laver J, Gbesemete D, Dale A, Pounce Z, Webb C, Roche E, et al.
Sci Transl Med
. 2021 Jul;
13(601).
PMID: 34233953
The human nasopharynx contains a stable microbial ecosystem of commensal and potentially pathogenic bacteria, which can elicit protective primary and secondary immune responses. Experimental intranasal infection of human adults with...
8.
Bewley K, Coombes N, Gagnon L, McInroy L, Baker N, Shaik I, et al.
Nat Protoc
. 2021 Apr;
16(6):3114-3140.
PMID: 33893470
Virus neutralization assays measure neutralizing antibodies in serum and plasma, and the plaque reduction neutralization test (PRNT) is considered the gold standard for measuring levels of these antibodies for many...
9.
Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer A, Ginn H, et al.
Cell
. 2021 Mar;
184(8):2201-2211.e7.
PMID: 33743891
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the...
10.
Salguero F, White A, Slack G, Fotheringham S, Bewley K, Gooch K, et al.
Nat Commun
. 2021 Feb;
12(1):1260.
PMID: 33627662
A novel coronavirus, SARS-CoV-2, has been identified as the causative agent of the current COVID-19 pandemic. Animal models, and in particular non-human primates, are essential to understand the pathogenesis of...